Consensus nomenclature for CD8+ T cell phenotypes in cancer

被引：121

作者：

Apetoh, Lionel ^{[1
,2
,3
]}

Smyth, Mark J. ^{[4
]}

Drake, Charles G. ^{[5
]}

Abastado, Jean-Pierre ^{[6
]}

Apte, Ron N. ^{[7
]}

Ayyoub, Maha ^{[8
]}

Blay, Jean-Yves ^{[9
,10
]}

Bonneville, Marc ^{[11
,12
]}

Butterfield, Lisa H. ^{[13
,14
,15
]}

Caignard, Anne ^{[16
]}

Castelli, Chiara ^{[17
]}

Cavallo, Federica ^{[18
]}

Celis, Esteban ^{[19
]}

Chen, Lieping ^{[20
,21
]}

Colombo, Mario P. ^{[22
]}

Comin-Anduix, Begona ^{[23
]}

Coukos, Georges ^{[24
]}

Dhodapkar, Madhav V.

Dranoff, Glenn ^{[25
,26
,27
,28
]}

Frazer, Ian H. ^{[29
]}

Fridman, Wolf-Herve ^{[30
]}

Gabrilovich, Dmitry I. ^{[31
]}

Gilboa, Eli ^{[32
]}

Gnjatic, Sacha ^{[33
]}

Jaeger, Dirk ^{[34
]}

Kalinski, Pawel ^{[35
]}

Kaufman, Howard L. ^{[36
]}

Kiessling, Rolf ^{[37
]}

Kirkwood, John ^{[38
,39
]}

Knuth, Alexander ^{[40
]}

Liblau, Roland ^{[41
,42
,43
,44
]}

Lotze, Michael T. ^{[45
]}

Lugli, Enrico ^{[46
]}

Marincola, Francesco ^{[47
]}

Melero, Ignacio ^{[48
]}

Melief, Cornelis J. ^{[49
]}

Mempel, Thorsten R. ^{[50
]}

Mittendorf, Elizabeth A. ^{[51
]}

Odun, Kunle ^{[52
,53
]}

Overwijk, Willem W. ^{[54
]}

Palucka, Anna Karolina ^{[55
]}

Parmiani, Giorgio ^{[56
]}

Ribas, Antoni ^{[23
]}

Romero, Pedro ^{[24
]}

Schreiber, Robert D. ^{[57
]}

Schuler, Gerold ^{[58
]}

Srivastava, Pramod K. ^{[59
]}

Tartour, Eric ^{[60
,61
]}

Valmori, Danila ^{[8
,62
]}

van der Burg, Sjoerd H. ^{[63
]}

机构：

[1] INSERM, UMR 866, Dijon, France

[2] Ctr Georges Francois Leclerc, Dijon, France

[3] Univ Bourgogne, Dijon, France

[4] QIMR Berghofer Med Res Inst, Herston, Qld, Australia

[5] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[6] Inst Rech Int Servier, Suresnes, France

[7] Ben Gurion Univ Negev, Fac Hlth Sci, Shraga Segal Dept Microbiol, Immunol & Genet, Beer Sheva, Israel

[8] INSERM, U1102, Equipe Labellisee Ligue Canc, Inst Cancerol Ouest, Nantes St Hreblain, France

[9] Canc Res Ctr Lyon, INSERM UMR 1052, CNRS UMR 5286, Ctr Leon Berard, Lyon, France

[10] Dept Med Oncol, Lyon, France

[11] CRCNA, INSERM U892, CNRS UMR 6299, Nantes, France

[12] Inst Merienx, Lyon, France

[13] Univ Pittsburgh, Inst Canc, Dept Med, Pittsburgh, PA USA

[14] Univ Pittsburgh, Inst Canc, Dept Surg, Pittsburgh, PA USA

[15] Univ Pittsburgh, Inst Canc, Dept Immunol, Pittsburgh, PA USA

[16] INSERM UMR 1116, Paris, France

[17] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Unit Immunotherapy Human Tumor, Milan, Italy

[18] Univ Turin, Ctr Mol Biotechnol, Dept Mol Biotechnol & Hlth Sci, I-10124 Turin, Italy

[19] Georgia Regents Univ, Ctr Canc, Canc Immunol, Inflammat & Tolerance Program, Augusta, GA USA

[20] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA

[21] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA

[22] Fdn IRCCS Ist Nazl Tumori, Mol Immunol Unit, Dept Expt Oncol & Mol Med, Milan, Italy

[23] Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr Los Angels, Los Angeles, CA 90024 USA

[24] Univ Lausanne, Dept Oncol, Ludwig Ctr Canc Res, CH-1015 Lausanne, Switzerland

[25] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[26] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA

[27] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA

[28] Harvard Univ, Sch Med, Boston, MA USA

[29] Univ Queensland, Brisbane, Qld 4072, Australia

[30] Univ Paris 05, Cordeliers Res Ctr, Paris, France

[31] Wistar Inst Anat & Biol, Translat Tumor Immunol, Philadelphia, PA 19104 USA

[32] Univ Miami, Miller Sch Med, Dodson Interdisciplinary Immunotherapy Inst, Dept Microbiol & Immunol,Sylvester Comprehens Can, Miami, FL USA

[33] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA

[34] Univ Heidelberg Hosp, Internal Med 4, Natl Ctr Tumor Dis, Dept Med Oncol, Heidelberg, Germany

[35] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA

[36] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[37] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden

[38] Univ Pittsburgh, Dept Med, Sch Med, Div Hematol Oncol, Pittsburgh, PA USA

[39] Univ Pittsburgh, Inst Canc, Melanoma & Skin Canc Program, Pittsburgh, PA USA

[40] Natl Ctr Canc Care & Res, Doha, Qatar

[41] INSERM UMR 1043, Toulouse, France

[42] CNRS, U5282, Toulouse, France

[43] Univ Toulouse, UPS, Ctr Physiopathol Toulouse Purpan, Toulouse, France

[44] CHU Toulouse Purpan, Toulouse, France

[45] Univ Pittsburgh, Sch Hlth Sci, Hillman Canc Ctr, Pittsburgh, PA USA

[46] Humanitas Clin & Res Ctr, Unit Clin & Expt Immunol, Rozzano, Italy

[47] Sidra Med & Res Ctr, Res Branch, Doha, Qatar

[48] Univ Navarra, Div Oncol, Ctr Appl Med Res & Clin, E-31080 Pamplona, Spain

[49] Leiden Univ, ISA Pharmaceut, NL-2300 RA Leiden, Netherlands

[50] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Immunol & Inflammatory Dis, Boston, MA USA

来源：

ONCOIMMUNOLOGY | 2015年 / 4卷 / 04期

基金：

英国医学研究理事会;

关键词：

anergy; anticancer immunity; CD8(+) T cells; cytotoxicity; exhaustion; effector; IFN gamma; senescence; stemness; CHRONIC VIRAL-INFECTION; ANTIGEN-LOSS VARIANTS; TUMOR-SPECIFIC CTL; ANTITUMOR IMMUNITY; REPLICATIVE SENESCENCE; MELANOMA PATIENTS; INTERFERON-GAMMA; DENDRITIC CELLS; IN-VITRO; INHIBITORY RECEPTORS;

D O I：

10.1080/2162402X.2014.998538

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Whereas preclinical investigations and clinical studies have established that CD8+ T cells can profoundly affect cancer progression, the underlying mechanisms are still elusive. Challenging the prevalent view that the beneficial effect of CD8+ T cells in cancer is solely attributable to their cytotoxic activity, several reports have indicated that the ability of CD8+T cells to promote tumor regression is dependent on their cytokine secretion profile and their ability to self-renew. Evidence has also shown that the tumor microenvironment can disarm CD8+ T cell immunity, leading to the emergence of dysfunctional CD8+ T cells. The existence of different types of CD8+ T cells in cancer calls for a more precise definition of the CD8+ T cell immune phenotypes in cancer and the abandonment of the generic terms “pro-tumor” and “antitumor.” Based on recent studies investigating the functions of CD8+ T cells in cancer, we here propose some guidelines to precisely define the functional states of CD8+T cells in cancer. © 2015 Taylor & Francis Group, LLC.

引用

页数：10

共 97 条

[1] Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure [J].

Abouzahr, S ;

Bismuth, G ;

Gaudin, C ;

Caroll, O ;

Van Endert, P ;

Jalil, A ;

Dausset, J ;

Vergnon, I ;

Richon, C ;

Kauffmann, A ;

Galon, J ;

Raposo, G ;

Mami-Chouaib, F ;

Chouaib, S .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (05) :1428-1433

[2] Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas [J].

Afshar-Sterle, Shoukat ;

Zotos, Dimitra ;

Bernard, Nicholas J. ;

Scherger, Anna K. ;

Roedling, Lisa ;

Alsop, Amber E. ;

Walker, Jennifer ;

Masson, Frederick ;

Belz, Gabrielle T. ;

Corcoran, Lynn M. ;

O'Reilly, Lorraine A. ;

Strasser, Andreas ;

Smyth, Mark J. ;

Johnstone, Ricky ;

Tarlinton, David M. ;

Nutt, Stephen L. ;

Kallies, Axel .

NATURE MEDICINE, 2014, 20 (03) :283-290

[3] Restoration of Antitumor Immunity Through Selective Inhibition of Myeloid Derived Suppressor Cells by Anticancer Therapies [J].

Apetoh, L. ;

Vegran, F. ;

Ladoire, S. ;

Ghiringhelli, F. .

CURRENT MOLECULAR MEDICINE, 2011, 11 (05) :365-372

[4] PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer [J].

Badoual, Cecile ;

Hans, Stephane ;

Merillon, Nathalie ;

Van Ryswick, Cordelia ;

Ravel, Patrice ;

Benhamouda, Nadine ;

Levionnois, Emeline ;

Nizard, Mevyn ;

Si-Mohamed, Ali ;

Besnier, Nicolas ;

Gey, Alain ;

Rotem-Yehudar, Rinat ;

Pere, Helene ;

Tran, Thi ;

Guerin, Coralie L. ;

Chauvat, Anne ;

Dransart, Estelle ;

Alanio, Cecile ;

Albert, Sebastien ;

Barry, Beatrix ;

Sandoval, Federico ;

Quintin-Colonna, Francoise ;

Bruneval, Patrick ;

Fridman, Wolf H. ;

Lemoine, Francois M. ;

Oudard, Stephane ;

Johannes, Ludger ;

Olive, Daniel ;

Brasnu, Daniel ;

Tartour, Eric .

CANCER RESEARCH, 2013, 73 (01) :128-138

[5] Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients [J].

Baitsch, Lukas ;

Baumgaertner, Petra ;

Devevre, Estelle ;

Raghav, Sunil K. ;

Legat, Amandine ;

Barba, Leticia ;

Wieckowski, Sebastien ;

Bouzourene, Hanifa ;

Deplancke, Bart ;

Romero, Pedro ;

Rufer, Nathalie ;

Speiser, Daniel E. .

JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (06) :2350-2360

[6] Restoring function in exhausted CD8 T cells during chronic viral infection [J].

Barber, DL ;

Wherry, EJ ;

Masopust, D ;

Zhu, BG ;

Allison, JP ;

Sharpe, AH ;

Freeman, GJ ;

Ahmed, R .

NATURE, 2006, 439 (7077) :682-687

[7] Cytotoxic T lymphocytes: All roads lead to death [J].

Barry, M ;

Bleackley, RC .

NATURE REVIEWS IMMUNOLOGY, 2002, 2 (06) :401-409

[8] Functional Unresponsiveness and Replicative Senescence of Myeloid Leukemia Antigen-specific CD8+ T Cells After Allogeneic Stem Cell Transplantation [J].

Beatty, Gregory L. ;

Smith, Jasmine S. ;

Reshef, Ran ;

Patel, Kunal P. ;

Colligon, Theresa A. ;

Vance, Barbara A. ;

Frey, Noelle V. ;

Johnson, F. Brad ;

Porter, David L. ;

Vonderheide, Robert H. .

CLINICAL CANCER RESEARCH, 2009, 15 (15) :4944-4953

[9] Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells [J].

Bettelli, E ;

Carrier, YJ ;

Gao, WD ;

Korn, T ;

Strom, TB ;

Oukka, M ;

Weiner, HL ;

Kuchroo, VK .

NATURE, 2006, 441 (7090) :235-238

[10] Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection [J].

Blackburn, Shawn D. ;

Shin, Haina ;

Haining, W. Nicholas ;

Zou, Tao ;

Workman, Creg J. ;

Polley, Antonio ;

Betts, Michael R. ;

Freeman, Gordon J. ;

Vignali, Dario A. A. ;

Wherry, E. John .

NATURE IMMUNOLOGY, 2009, 10 (01) :29-37

← 1 2 3 4 5 6 7 8 9 10 →